This content is only available for ASCRS Members
ASCRS Membership offers access to 1,000+ educational resources on demand.
Learn More About ASCRS Membership
Since the bioerodible, sustained-release dexamethasone intraocular suspension 9% was approved for postoperative inflammation, surgeons have been working to optimize its administration. Most recently, we have found success injecting the drug directly into the capsular bag, adjacent to the intraocular lens implant. This video will demonstrate strategies for success with intracapsular delivery.